NIFTY 50▼24,795.75
-218.85 (-0.87%)
SENSEX▼81,050.00
-638.45 (-0.78%)
NIFTY BANK▼50,478.90
-983.15 (-1.91%)
TATA MOTORS▼927.85
-2.90 (-0.31%)
SUZLON ENERGY▼70.93
-3.74 (-5.01%)
TATA STEEL▼164.36
-2.39 (-1.43%)
INDIAN RAILWAY FINANCE CORP▼144.35
-7.72 (-5.08%)
TATA POWER▼441.30
-25.35 (-5.43%)
RAIL VIKAS NIGAM▼451.70
-41.70 (-8.45%)
VODAFONE IDEA▼9.16
-0.63 (-6.44%)
RELIANCE INDUSTRIES▼2,741.45
-31.60 (-1.14%)
INDIAN RENEWABLE ENERGY▼211.13
-10.53 (-4.75%)
ZOMATO▼266.10
-9.20 (-3.34%)
RELIANCE POWER▼48.40
-2.55 (-5.00%)
ADANI POWER▼625.45
-16.65 (-2.59%)
YES BANK▼21.26
-0.69 (-3.14%)
STATE BANK OF INDIA▼770.65
-26.00 (-3.26%)
NHPC▼90.47
-2.70 (-2.90%)
HDFC BANK▼1,617.80
-39.85 (-2.40%)
JIO FIN SERVICES LTD▼336.35
-2.45 (-0.72%)
OLA ELECTRIC MOBILITY LTD▼90.82
-8.23 (-8.31%)
BHARAT ELECTRONICS▼267.35
-9.85 (-3.55%)
INDIAN OIL CORP▼162.74
-5.91 (-3.50%)
ADANI PORT & SEZ▼1,355.20
-58.50 (-4.14%)
GTL INFRA▼2.19
-0.12 (-5.19%)
MRF▼1,31,237.85
-2170.90 (-1.63%)
JAIPRAKASH POWER VENTURES▼18.45
-0.98 (-5.04%)
INDIAN RAILWAY TOURISM CORP▼857.70
-15.05 (-1.72%)
Suven Life Sciences Share Price
SUVEN
₹134.70-₹7.45 (-5.24%) TodayLast updated on 07 Oct, 2024 | 15:50 IST
Please wait...
What’s in news?
Company overview
Financial performance
Market cap
| Open₹142.15 | Close₹142.15 |
Circuit range₹161.64 - ₹107.76 | Day range₹130.00 - ₹142.75 | Year range₹60.75 - ₹169.30 |
Volume4,50,575 | Avg. traded₹135.48 | Revenue (12m)₹9 Crs |
Suven Life SciencesSuven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (?4?2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
Suven Life Sciences Key indicators
52 week high₹169.30 | 52 week low₹60.75 | P/E ratio |
P/B ratio12.78 | ROE-0.94% | ROCE-1.03% |
Dividend yield-- | Debt/Equity ratio | EPS-0.37 |
Learn more
Featured in
Investment checklist: (2/6)
Equity returns
Dividend returns
Safety factor
Growth factor
Debt vs Equity
Profit factor
The investment checklist helps you understand a company's financial health at a glance and identify quality investment opportunities easily
Analyst ratings:
Analyst ratings:
100%
Hold
0%
Sell
0%
This analysis is based on the reviews of 1 experts in the last 7 days
Fundamentals
Financial ratios
Operating profit margin-83.17% | Net profit margin-68.49% |
ROE-0.94% | ROA-0.89% |
ROCE-1.03% |
Learn more
Suven Life Sciences Share Price history
Day | Open | Close | Day’s change |
---|---|---|---|
Mon, Oct 7 2024 | ₹142.15 | ₹134.70 | -5.24% |
Fri, Oct 4 2024 | ₹141.50 | ₹142.15 | |
Thu, Oct 3 2024 | ₹141.07 | ₹141.84 | -2.86% |
Tue, Oct 1 2024 | ₹140.70 | ₹146.02 | |
Mon, Sep 30 2024 | ₹144.00 | ₹140.69 | -1.68% |
Fri, Sep 27 2024 | ₹142.00 | ₹143.10 | |
Thu, Sep 26 2024 | ₹143.70 | ₹140.89 | -1.96% |
Wed, Sep 25 2024 | ₹147.70 | ₹143.70 | -2.24% |
Events
Corporate actions
Rights Issue • 1:2
Ex date 17 Oct 2022
Learn more